314 related articles for article (PubMed ID: 28460360)
1. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological activity of 4-(4-benzyloxy)phenoxypiperidines as selective and reversible LSD1 inhibitors.
Xi J; Xu S; Zhang L; Bi X; Ren Y; Liu YC; Gu Y; Xu Y; Lan F; Zha X
Bioorg Chem; 2018 Aug; 78():7-16. PubMed ID: 29524666
[TBL] [Abstract][Full Text] [Related]
3. Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation.
Duan YC; Guan YY; Zhai XY; Ding LN; Qin WP; Shen DD; Liu XQ; Sun XD; Zheng YC; Liu HM
Eur J Med Chem; 2017 Jan; 126():246-258. PubMed ID: 27888721
[TBL] [Abstract][Full Text] [Related]
4. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
6. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Selective Lysine-Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore-Based Virtual Screening Combined with Docking.
Zhou C; Kang D; Xu Y; Zhang L; Zha X
Chem Biol Drug Des; 2015 Jun; 85(6):659-71. PubMed ID: 25346381
[TBL] [Abstract][Full Text] [Related]
8. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel (E)-N'-(2,3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors.
Zhou Y; Li Y; Wang WJ; Xiang P; Luo XM; Yang L; Yang SY; Zhao YL
Bioorg Med Chem Lett; 2016 Sep; 26(18):4552-4557. PubMed ID: 27524309
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of tetrahydroquinoline-based reversible LSD1 inhibitors.
Wang X; Zhang C; Zhang X; Yan J; Wang J; Jiang Q; Zhao L; Zhao D; Cheng M
Eur J Med Chem; 2020 May; 194():112243. PubMed ID: 32229389
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
15. LSD1 Histone Demethylase Assays and Inhibition.
Hayward D; Cole PA
Methods Enzymol; 2016; 573():261-78. PubMed ID: 27372757
[TBL] [Abstract][Full Text] [Related]
16. Drug Design Concepts for LSD1-Selective Inhibitors.
Ota Y; Suzuki T
Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
Zhang X; Huang H; Zhang Z; Yan J; Wu T; Yin W; Sun Y; Wang X; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2021 Aug; 220():113501. PubMed ID: 33945992
[TBL] [Abstract][Full Text] [Related]
18. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
[TBL] [Abstract][Full Text] [Related]
20. Hologram quantitative structure-activity relationship and comparative molecular interaction field analysis of aminothiazole and thiazolesulfonamide as reversible LSD1 inhibitors.
Maltarollo VG; Honório KM; Emery FS; Ganesan A; Trossini GH
Future Med Chem; 2015; 7(11):1381-94. PubMed ID: 26230878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]